Gould Robert J 4
4 · Fulcrum Therapeutics, Inc. · Filed Jul 2, 2026
Research Summary
AI-generated summary of this filing
Fulcrum (FULC) Director Robert J. Gould Receives Award
What Happened
Robert J. Gould, a director of Fulcrum Therapeutics, received a derivative equity award on June 30, 2026. The Form 4 reports an acquisition of rights to 32,000 shares at $0.00 (recorded as a derivative award rather than an open‑market purchase or sale). This is a grant of equity compensation, not a stock sale or cash purchase.
Key Details
- Transaction date and type: 2026-06-30 — Grant/Award (code A) of a derivative equity instrument for 32,000 shares, reported at $0.00.
- Shares owned after transaction: Not specified in this filing.
- Vesting: The award vests in full on the first anniversary of the grant (June 30, 2027) or, if earlier, immediately prior to the first annual meeting after the grant, subject to continued service (footnote F1).
- Filing timeliness: Reported on Form 4 filed July 2, 2026; this appears to be a timely filing (within the usual two-business-day window).
Context
This was an equity compensation grant to a board member — commonly used for director compensation and not a direct market purchase or sale. The $0.00 amount reflects the reporting of a derivative award on the Form 4; the filing does not disclose strike price or immediate economic value. Such grants are routine corporate compensation and do not by themselves signal insider buying or selling intent.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-06-30+32,000→ 32,000 totalExercise: $3.66Exp: 2036-06-29→ Common Stock (32,000 underlying)
Footnotes (1)
- [F1]This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.